MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202641123919 A) filed by Vellore Institute Of Technology on October 16, 2026, for Screening Pipeline For Identification Of Plant-Derived Inhibitors Of Viral Rna-Dependent Rna Polymerase And Rosmariquinone-Based Antiviral Compositions Obtained Therefrom.
Inventors include Kuntal Pal; and Krishna Sayantika Deb.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The invention provides a computer-implemented pipeline for identifying plant-derived inhibitors of viral RNA-dependent RNA polymerase (RdRp), and antiviral compositions obtained therefrom. RdRp structures of a plurality of RNA viruses are retrieved or built as validated homology models; a plant-derived ligand and a reference nucleoside analogue are energy-minimised and subjected to blind and thereafter site-specific docking; a binding pocket occupied by both and conserved across the said viruses is identified by superimposition; and the resulting complexis validated by moleculardynamics simulation of about 300 nanoseconds. The pipeline identifies Rosmariquinone, a diterpenoid quinone from Rosmarinus officinalis, as occupying the nucleoside-binding pocket shared with Remdesivir and conserved across severe acute respiratory syndrome coronavirus 2, Marburg, Nipah, Dengue and Chandipura virus polymerases. In infected Vero E6 cells, Rosmariquinone dose- dependently suppresses viral nucleocapsid translation and RdRp and ORF1a transcription, suppression being substantially complete at about 20 µM, the half-maximal effective concentration being about 7.5 µM as against about 26.90 µM reported for Remdesivir upon an equivalent endpoint in the same cell line.
Disclaimer: Curated by HT Syndication.
